PharmAla Comments on USFDA Decision regarding MDMA-Assisted Therapy and Announces Patent Granting for ALA-002
09 août 2024 18h18 HE
|
PharmAla Biotech
PharmAla expresses disappointment in USFDA's decision to request a third Phase 3 for MDMA and announces the patent granting for a safer MDMA analog variant
PharmAla Submits Pre-IND Dossier for Novel MDMA Analog to FDA
02 nov. 2022 09h00 HE
|
PharmAla Biotech
VANCOUVER, British Columbia, Nov. 02, 2022 (GLOBE NEWSWIRE) -- PharmAla Biotech (CSE:MDMA) is pleased to announce that it has submitted its pre-IND data meeting package to the US Food and Drug...
Jubilant Radiopharma Receives Approval from Health Canada for Drax Exametazime®
27 janv. 2020 16h05 HE
|
Jubilant Pharma
YARDLEY, Pa., Jan. 27, 2020 (GLOBE NEWSWIRE) -- Jubilant Radiopharma, the Radiopharmaceutical Division of Jubilant Pharma Ltd, announced today that the company received approval from Health Canada...
Lexington Announces Non-Brokered Private Placement
27 août 2018 09h00 HE
|
Lexington Biosciences, Inc.
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN VANCOUVER, British Columbia, Aug. 27,...